These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 15537481)

  • 1. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective.
    Vicente-Herrero T; Burke TA; Laínez MJ
    Curr Med Res Opin; 2004 Nov; 20(11):1805-14. PubMed ID: 15537481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study.
    Láinez MJ; López A; Pascual AM
    Headache; 2005; 45(7):883-90. PubMed ID: 15985105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Company reference estimates for productivity loss due to migraine and productivity gains using rizatriptan 10 mg in Germany.
    Yoon MS; Katsarava Z; Liedert B; Krobot KJ; Diener HC; Limmroth V
    Int J Clin Pract; 2006 Mar; 60(3):295-9. PubMed ID: 16494644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
    Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
    Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
    Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
    Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Munakata J; Hazard E; Serrano D; Klingman D; Rupnow MF; Tierce J; Reed M; Lipton RB
    Headache; 2009 Apr; 49(4):498-508. PubMed ID: 19245386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
    Lo Sasso AT; Rost K; Beck A
    Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model.
    Gerth WC; Sarma S; Hu XH; Silberstein SD
    J Occup Environ Med; 2004 Jan; 46(1):48-54. PubMed ID: 14724478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of migraine and migraine therapy on productivity and quality of life.
    Solomon GD; Santanello N
    Neurology; 2000; 55(9 Suppl 2):S29-35. PubMed ID: 11089517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial.
    Lambert J; Carides GW; Meloche JP; Gerth WC; Marentette MA
    Can J Clin Pharmacol; 2002; 9(3):158-64. PubMed ID: 12422253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective.
    Lamb CE; Ratner PH; Johnson CE; Ambegaonkar AJ; Joshi AV; Day D; Sampson N; Eng B
    Curr Med Res Opin; 2006 Jun; 22(6):1203-10. PubMed ID: 16846553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey--Phase III.
    MacGregor EA; Brandes J; Eikermann A; Giammarco R
    Curr Med Res Opin; 2004 Jul; 20(7):1143-50. PubMed ID: 15265259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of headache in a population of health care workers and the effects on productivity costs.
    Cristofolini A; Dalla Serra P; Scherillo G; Orrico D; Micciolo R
    Med Lav; 2008; 99(1):8-15. PubMed ID: 18254535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan.
    Goldstein J; Tiseo PT; Albert KS; Li C; Sikes CR
    Headache; 2006; 46(7):1142-50. PubMed ID: 16866718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining the utility of in-clinic "rescue" therapy for acute migraine.
    Morey V; Rothrock JF
    Headache; 2008 Jun; 48(6):939-43. PubMed ID: 18549372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total costs of IBS: employer and managed care perspective.
    Cash B; Sullivan S; Barghout V
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting.
    Baos V; Serrano A; Torrecilla M; Bertral C; Caloto MT; Nocea G; Gerth WC;
    Int J Clin Pract; 2003 Nov; 57(9):761-8. PubMed ID: 14686564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
    McCormack PL; Foster RH
    Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference.
    Pascual J; García-Moncó C; Roig C; Yusta Izquierdo A; López-Gil A;
    Headache; 2005 Oct; 45(9):1140-50. PubMed ID: 16178944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical care for migraine and headache patients: a community-based, randomized intervention.
    Hoffmann W; Herzog B; Mühlig S; Kayser H; Fabian R; Thomsen M; Cramer M; Fiss T; Gresselmeyer D; Janhsen K
    Ann Pharmacother; 2008 Dec; 42(12):1804-13. PubMed ID: 19001531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.